Publication: 2505

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)
      QxMD      Google Scholar   
Citation:
J Thorac Oncol vol 12 (5) 843-849
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
6
Parents:
2094   2132   2204  
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
Health Outcomes    
Pharmas:
 
Grants:
CA31946, CA33601, U10CA180821, U10CA180882, U10CA180790, U10CA180838, U10CA180833, U10CA180836, U10CA180857, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA180836, U10 CA180857, U10 CA180790, U10 CA180882, U10 CA180833, U10 CA180838, U10 CA180844  
Corr. Author:
 
Authors:
                         
Networks:
FL086, LAPS-IL057, LAPS-MD017, LAPS-MO011, LAPS-NC010, MD015, VCU   
Study
CALGB-30607
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-70701
Phases:
3, N/A
Keywords:
Sunitinib, Maintenance, NSCLC, Tyrosine kinase inhibitor